CEO Total Pay
$473K
FY2023 Summary Compensation, below median
The CEO earned $473K in FY2023 against median worker pay of $236,291 · Chemicals & Pharmaceuticals.
Data updated August 2026
Subscribe to Lyell Immunopharma, Inc. CEO pay filing updates (RSS)
Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
A component-level pay breakdown is not reported in Lyell Immunopharma, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Lyell Immunopharma, Inc. stamps FLOOR · ELITE-MED at 2:1 against $236,291 median worker pay in FY2023. the CEO earned 2× the median employee ($236,291) in FY2023.
At $236,291 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.
CEO Total Pay
$473K
FY2023 Summary Compensation, below median
Pay Ratio
2:1
Below typical
Lyell Immunopharma, Inc. stamps FLOOR · ELITE-MED at 2:1 against $236,291 median worker pay in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Lyell Immunopharma, Inc.'s $473K CEO total is at or below the $7.9M industry median CEO pay.
Lyell Immunopharma, Inc. stamps FLOOR · MICRO · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Read our methodology - how this data is sourced, computed, and verified. Lyell Immunopharma, Inc. stamps FLOOR · ELITE-MED at 2:1 against $236,291 median worker pay in FY2023.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $477K (Δ $4K heavier vs Lyell Immunopharma, Inc.); FLOOR · PAR-MED vs this page's FLOOR · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $465K (Δ $8K lighter vs Lyell Immunopharma, Inc.); FLOOR · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $462K (Δ $10K lighter vs Lyell Immunopharma, Inc.); FLOOR · PAR-MED vs this page's FLOOR · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $456K (Δ $17K lighter vs Lyell Immunopharma, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · MICRO · ELITE-MED.
Lyell Immunopharma, Inc. stamps FLOOR · MICRO · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
See where FLOOR · MICRO packages sit on the national leaderboard after reading Lyell Immunopharma, Inc..
Lyell Immunopharma, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.